首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

【24h】

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

机译：曾接受注射性次甲基化剂（HMA）治疗的血液系统恶性肿瘤患者的CC-486（口服阿扎胞苷）：1/2 CC-486期研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共8页
作者
Garcia-Manero Guillermo; Savona Michael R.; Gore Steven D.; Scott Bart L.; Cogle Christopher R.; Boyd Thomas; Conkling Paul; Hetzer Joel; Dong Qian; Kumar Keshava; Ukrainskyj Stacey M.; Skikne Barry S.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies [J] . Garcia-Manero Guillermo, Savona Michael R., Gore Steven D., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：曾接受注射性次甲基化剂（HMA）治疗的血液系统恶性肿瘤患者的CC-486（口服阿扎胞苷）：1/2 CC-486期研究的结果
2. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies [J] . LailleE., SavonaM.R., ScottB.L., The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2014,第6期

机译：口服氮酰硝基（CC-486）不同配方的药代动力学及食品和改性胃水pH对血液学恶性肿瘤药代动力学的影响
3. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors [J] . Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Journal for ImmunoTherapy of Cancer . 2020,第2期

机译：口服甲基化剂CC-486和晚期实体肿瘤中的OID的开放标签，II次多伐花研究
4. Designing a conversational agent for patients with hematologic malignancies: Usability and Usefulness Study [C] . Maria Chatzimina, Helen Papadaki, Charalampos Pontikoglou, IEEE EMBS International Conference on Biomedical and Health Informatics . 2021

机译：设计血液学恶性肿瘤患者的会话剂：可用性和有用性研究
5. Impact of Dose Received by the Oral Cavity on Patient Reported Outcomes in the Setting of Deescalated Radiotherapy Treatment [D] . Fuquay, Andrew T. 2020

机译：口腔对患者口腔接受的影响报告了欺骗放疗治疗的结果
6. An open-label phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors [O] . Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, 2020

机译：口服甲基化剂CC-486和晚期实体肿瘤中的OID的开放标签II次多伐花研究
7. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia [O] . Garcia-Manero, G, Almeida, A, Giagounidis, A, 2016

机译：QUAZAR低危MDS（AZA-MDS-003）试验的设计和原理：CCSS-486（口服阿扎胞苷）+最佳支持治疗与安慰剂+最佳支持治疗的IPSS低危骨髓增生异常患者的3期随机研究红细胞输血依赖性贫血和血小板减少症引起的综合征和预后不良

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号